By Cocer Peptides 
1 ọnwa gara aga
Edemede na ozi ngwaahịa niile enyere na webụsaịtị a bụ naanị maka mgbasa ozi na ebumnuche mmụta.
Ngwaahịa ndị enyere na webụsaịtị a bụ naanị maka nyocha in vitro. A na-eme nyocha in vitro (Latin: * na iko *, nke pụtara na ihe eji enyo) na mpụga ahụ mmadụ. Ngwaahịa ndị a abụghị ọgwụ, ndị US Food and Drug Administration (FDA) akwadoghị ya, ha agaghịkwa eji ya gbochie, gwọọ, ma ọ bụ gwọọ ọnọdụ ahụike ọ bụla, ọrịa, ma ọ bụ ọrịa. Iwu amachibidoro nke ọma iwebata ngwaahịa ndị a n'ime ahụ mmadụ ma ọ bụ anụmanụ n'ụdị ọ bụla.
1 Nchịkọta
Ụdị ọrịa shuga 2dị nke Abụọ (T2D) bụ ọrịa metabolic na-adịghị ala ala nke a na-eji nguzogide insulin na ụkọ insulin ezughi oke, na-eduga n'ọkwa glucose dị elu. Site na mmụba zuru ụwa ọnụ na ọnụ ọgụgụ oke ibu, ihe omume nke T2D na-aga n'ihu na-abawanye. Ijikwa ibu dị oke mkpa na ọgwụgwọ T2D, n'ihi na oke ibu na-emekarị ka nguzogide insulin dịkwuo elu ma na-emebikwa njikwa glucose ọbara. Ịmepụta ọgwụ ndị nwere ike ịhazi ọkwa glucose ọbara n'ụzọ dị irè mgbe ị na-enyere aka na njikwa ibu aghọwo ihe nyocha na-elekwasị anya na ngalaba ọgwụgwọ T2D. Cagrilintide, dị ka ọgwụ ọhụrụ, na-adọtakwu uche.
Nyocha 1 Mmetụta ọrịa shuga na oke ibu nke GLP-1.
2 Ọrụ Cagrilintide na Iwu Glucose Ọbara
Usoro nhazi
Cagrilintide bụ glucagon dị ka peptide-1 (GLP-1). GLP-1 bụ homonụ incretin nke na-arụ ọrụ dị mkpa na nhazi glucose ọbara. Mgbe nri gasịrị, mkpụrụ ndụ endocrine nke eriri afọ na-ezobe GLP-1, nke na-akpali mmepụta insulin n'ụzọ dabere na mkpokọta glucose, si otú a na-ebelata ọkwa glucose ọbara. Cagrilintide nwere mmekọrịta dị elu maka ndị na-anabata GLP-1 ma nwee ike iṅomi mmetụta physiological nke GLP-1. Mgbe ọkwa glucose ọbara na-ebili, Cagrilintide na-ejikọ ya na onye na-anabata GLP-1, na-arụ ọrụ usoro ụzọ mgbaàmà intracellular na-akwalite njikọ insulin na ntọhapụ, na-eme ka glucose banye sel maka ojiji wee si otú a na-ebelata mkpokọta glucose ọbara. Ọ na-egbochi secretion glucagon ma na-ebelata mmepụta glucose imeju, na-eme ka ọkwa glucose dị n'ọbara kwụsie ike.
Ịrụ ọrụ ụlọ ọgwụ
Ọtụtụ ọmụmụ ụlọ ọgwụ egosila na Cagrilintide na-egosipụta mmetụta nchịkwa glucose ọbara dị mma na ndị ọrịa nwere ụdị ọrịa shuga 2. N'ime usoro ọgwụgwọ, nke kpuru ìsì abụọ, nke a na-achịkwa ebebo, ndị ọrịa T2D kewara n'ime otu ọgwụgwọ Cagrilintide na otu placebo. Mgbe izu iri na abụọ gachara ọgwụgwọ, achọpụtara na ndị ọrịa nọ na otu ọgwụgwọ Cagrilintide nwere mbelata dị ukwuu na haemoglobin A1c (HbA1c) ma e jiri ya tụnyere ntọala, yana mbelata pụtara ìhè na glucose ọbara na-ebu ọnụ na ọkwa glucose ọbara postprandial. HbA1c bụ ihe dị mkpa na-egosi njikwa glucose ọbara na-adịte aka, na mbelata ya na-egosi na Cagrilintide nwere ike imeziwanye njikwa glucose ọbara nke ọma na nke ọma. E jiri ya tụnyere ọgwụ antidiabetic ọdịnala, Cagrilintide na-ebelata ọkwa glucose ọbara ma na-etinye obere ihe ize ndụ nke hypoglycemia. A na-ekwu na nke a bụ usoro nke na-akwalite mmepụta insulin nke na-adabere na glucose na-adabere na ya, nke pụtara na ọ na-akpali mmepụta insulin naanị mgbe ọkwa glucose dị n'ọbara na-ebili ma ghara ibelata ọkwa glucose ọbara gabiga ókè mgbe ọ dị mma.
3 Usoro nke Omume nke Cagrilintide na njikwa ibu
Cagrilintide na-ebelata oriri site na igbochi agụụ. Ọ na-arụ ọrụ na usoro nhụjuanya nke etiti, na-emetụta ebe satiety center na hypothalamus iji mee ka mmetụta nke zuru oke, si otú ahụ belata oriri. Cagrilintide nwere ike igbu oge ịpụsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịtatata, na-agbatịkwu oge nri na-adị n’afọ, na-eme ka satiety dịkwuo elu, na ibelata oriri na-esote. Ọ nwekwara ike imetụta metabolism abụba site n'ịkwalite oxidation abụba na ịba ụba ume ike, si otú a na-enyere aka mbelata ibu.
4 Ngwa nke Cagrilintide na ọgwụgwọ ụdị ọrịa shuga 2
Ngosipụta
Cagrilintide dabara adaba maka ọtụtụ ndị ọrịa nwere ụdị ọrịa shuga 2, ọkachasị ndị nwere oke ibu ma ọ bụ oke ibu. Maka ndị ọrịa nwere njikwa glycemic na-adịghị mma n'agbanyeghị nri na mmega ahụ ma na-achọ njikwa ibu otu oge, Cagrilintide bụ nhọrọ ọgwụgwọ dị mma.
Ngwakọta na ọgwụ ndị ọzọ
Enwere ike iji Cagrilintide yana ọgwụ antidiabetic ọdịnala dị iche iche, dị ka metformin na sulfonylureas. Usoro ọgwụgwọ nchikota nwere ike itinye mmetụta synergistic nke ọgwụ dị iche iche iji chịkwaa shuga na ibu ọbara n'ụzọ zuru ezu karị. Mgbe ejikọtara ya na metformin, metformin na-ebute ụzọ belata shuga ọbara site na ịkwalite nguzogide insulin na ibelata mmepụta glucose imeju, ebe Cagrilintide na-ebelata shuga ọbara na ibu site na usoro dị ka ịkwalite insulin secretion na igbochi agụụ. Ngwakọta nke abụọ ahụ nwere ike ịchịkwa ọkwa shuga dị n'ọbara nke ọma na ndị ọrịa T2D ma na-abawanye ọkwa ịdị arọ na-enweghị ịbawanye ohere nke mmeghachi omume ọjọọ dị ka hypoglycemia.
5 Nkwubi okwu
Na nchịkọta, Cagrilintide, dị ka ọgwụ ọhụrụ maka ọgwụgwọ ụdị ọrịa shuga 2, na-egosipụta ịdị mma na nhazi ọkwa glucose ọbara na njikwa ibu. Usoro ya na-eme ka ọ baa uru ngwa ngwa na ọgwụgwọ T2D, na-enye nhọrọ ọgwụgwọ ọhụrụ maka ndị ọrịa nwere ụdị ọrịa shuga 2.
Isi mmalite
[1] Abdulrahman A, Najjar S, Al-Zobaidy M. Mmetụta nke liraglutide na njikwa ibu na ọbara mgbali n'ụdị ọrịa shuga 2 Mmetụta nke liraglutide na njikwa ibu na ọbara mgbali elu na ụdị 2 ọrịa shuga mellitus ndị Iraq [J]. Akwụkwọ akụkọ nke ngalaba ọgwụ, Baghdad, 2023,64:2022.DOI:10.32007/jfacmedbagdad.6441971.
[2] Kurtzhals P, Flindt Kreiner F, Singh Bindra R. Ọrụ njikwa ibu na njikwa ụdị ọrịa shuga mellitus 2: Echiche na semaglutide [J]. Nnyocha ọrịa shuga na omume ụlọ ọgwụ, 2023,203.DOI:10.1016/j.diabres.2023.110881.
[3] Shalahuddin I, Maulana I, Pebrianti S, et al. Iwu ọkwa shuga ọbara na ọrịa shuga mellitus ụdị 2 site na njikwa nri [J]. Jurnal Aisyah : Jurnal Ilmu Kesehatan, 2022. https://api.semanticscholar.org/CorpusID:251675212.
[4] McAdam-Marx C, Gaebler JA, Bellows BK, et al. Nlekọta oge a nke ndị ọrịa nwere ụdị ọrịa shuga 2[J]. Nyochaa ọkachamara nke ọgwụgwọ obi obi, 2010,8 (6): 767-770.DOI: 10.1586 / erc.10.62.
Ngwaahịa dị maka naanị nyocha:
